Sintx Technologies, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
SINTX raised ~$5M in Q2 2026 via private placement and ATM facility. The company launched limited commercial release of FDA-cleared SiNAPTIC Foot Ankle implant with 12 orthopedic distributors and received $3.2M in new industrial ceramic orders (revenue expected Q3–Q4 2026). Management guides Q3 2026 revenue to $900K–$1.1M and Q4 2026 to $1.0M–$1.3M, alongside cost-optimization initiatives and continued R&D in silicon nitride composites and antipathogenic products.
Why this rating
Capital raise and early commercial traction material for $7.7M company; revenue guidance and $3.2M order backlog represent real revenue visibility. Launch execution and diversified pipeline reduce single-product risk but remain execution-dependent.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.